US20090264520A1 - Lipid-containing compositions and methods of use thereof - Google Patents

Lipid-containing compositions and methods of use thereof Download PDF

Info

Publication number
US20090264520A1
US20090264520A1 US12/426,034 US42603409A US2009264520A1 US 20090264520 A1 US20090264520 A1 US 20090264520A1 US 42603409 A US42603409 A US 42603409A US 2009264520 A1 US2009264520 A1 US 2009264520A1
Authority
US
United States
Prior art keywords
composition
percent
weight
oil present
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/426,034
Other languages
English (en)
Inventor
Urvashi Bhagat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asha Nutrition Sciences Inc
Asha Lipid Sciences Inc
Original Assignee
Asha Lipid Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asha Lipid Sciences Inc filed Critical Asha Lipid Sciences Inc
Priority to US12/426,034 priority Critical patent/US20090264520A1/en
Assigned to ASHA LIPID SCIENCES, INC. reassignment ASHA LIPID SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BHAGAT, URVASHI
Priority to CA2759551A priority patent/CA2759551C/en
Priority to KR1020177033162A priority patent/KR102038118B1/ko
Priority to EP17182663.9A priority patent/EP3305083A1/en
Priority to PCT/US2009/041114 priority patent/WO2009131939A2/en
Priority to KR1020107026029A priority patent/KR102030851B1/ko
Priority to AU2009239499A priority patent/AU2009239499C1/en
Priority to EP09735962.4A priority patent/EP2278885A4/en
Priority to JP2011506377A priority patent/JP2011518223A/ja
Priority to MX2010011544A priority patent/MX2010011544A/es
Priority to MYPI2010004944A priority patent/MY157040A/en
Priority to NZ589357A priority patent/NZ589357A/en
Priority to CN2009801232357A priority patent/CN102065699A/zh
Priority to EA201071206A priority patent/EA201071206A1/ru
Priority to NZ602820A priority patent/NZ602820A/en
Priority to BRPI0910852A priority patent/BRPI0910852A2/pt
Publication of US20090264520A1 publication Critical patent/US20090264520A1/en
Priority to MX2019010738A priority patent/MX2019010738A/es
Priority to IL208858A priority patent/IL208858A/en
Priority to ZA2010/08232A priority patent/ZA201008232B/en
Priority to CO10145300A priority patent/CO6321198A2/es
Assigned to ASHA LIPID SCIENCES, INC. reassignment ASHA LIPID SCIENCES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BHAGAT, URVASHI
Priority to US13/332,251 priority patent/US10292958B2/en
Assigned to ASHA NUTRITION SCIENCES, INC. reassignment ASHA NUTRITION SCIENCES, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ASHA LIPID SCIENCES, INC.
Priority to JP2014099072A priority patent/JP7007010B2/ja
Priority to JP2017216717A priority patent/JP2018064563A/ja
Priority to JP2020019671A priority patent/JP6879597B2/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Definitions

  • Fatty acids play important physiological functions. They are the building blocks of phospholipids and glycolipids, crucial components of cell membranes. Fatty acids are the best biological fuel molecules, capable of yielding more than twice as much energy per gram as produced by carbohydrate or protein. Fatty acids directly affect the functions of many proteins through covalent modifications of such proteins. Fatty acids also affect membrane fluidity and associated cellular processes. Fatty acids' derivatives are also important hormones and biological messengers, e.g., prostaglandins, thromboxanes, leukotrienes, lipoxins, and resolvins. These hormones and messengers affect a broad range of physiological functions such as vasal dilation, platelets aggregation, pain modulation, inflammation, and cell growth.
  • the human and animal bodies synthesize many kinds of fatty acids of various length of the carbon chain, with various numbers and locations of double bonds.
  • the addition of double bonds into a fatty acid chain converts it into an unsaturated fatty acid, which play significant roles in physiological functions.
  • One way of tracking the location of the double bond in an unsaturated fatty acid molecule is by its distance from the distal carbon, i.e., the omega-carbon.
  • the omega-carbon 18-carbon oleic acid, which has a double bond at the 9 th carbon from the omega position
  • Table 1 describes various unsaturated fatty acid groups named according to their double bond locations relative to the omega position:
  • LA and ALA are the precursors for all omega-6 and omega-3 fatty acids.
  • LA and ALA are “essential” fatty acids. They must be supplied in the diet because the human and other mammalians cannot synthesize them from other sources. Dietary deficiency or excess of the two essential fatty acids may cause many illnesses. It is also well known that LA and ALA share the same metabolic pathways, and that the excess of one can increase the need for, or create a deficiency of, the other. The latest science also shows evidence that non-essential fatty acids can interfere with the activity and metabolism of essential fatty acids, and that the quantity of dietary fat can also influence the metabolism of fatty acids. ALA is known to be preferentially metabolized by the human body depending on the amount of the other fatty acids present in the diet.
  • omega-3 content in these lipid formulations was several-fold higher than that of omega-6.
  • lipid compositions used for diabetic patients which contained omega-3, omega-6, and omega-9 fatty acids, with the specific ratio of omega-6 to omega-3 being between 0.25:1 to 3:1.
  • the present disclosure relates to compositions and methods for prophylaxis and/or treatment of medical conditions linked with an imbalance in one or more lipids within context of other factors. More particularly, the present disclosure relates to the use of compositions and methods that use more advantageous sources of omega-6 fatty acids, in the presence of nutritionally adequate omega-3 fatty acids. The disclosure also relates to methods and compositions that deliver omega-6 and omega-3 fatty acids along with other nutrients that optimize the daily delivery and bioavailability of omega-6 and omega-3 for prophylaxis and/or treatment of medical conditions linked with an imbalance in one or more lipids. This disclosure also relates to methods of steady delivery of the bioactive substances, daily, weekly, monthly or longer duration wide and sudden fluctuations of which may be harmful. Furthermore, this disclosure also relates to methods of daily delivery of essential fatty acids within the optimal range with respect to the recommendations.
  • One general embodiment of the present disclosure is a lipid-containing composition
  • a lipid-containing composition comprising optimal amounts of fatty acids and phytochemicals for a mammalian subject based on one or more factors selected from the group including the subject's age, sex, diet, bodyweight, medical conditions, and the climate of the subject's living area.
  • Such composition is administered to a subject through a steady delivery process, as explained later, according to one embodiment of the disclosure.
  • the fatty acid components of the composition's lipid contents are achieved at least in part by using one or more of the following concentrated lipid sources: oils, butters, nuts, and seeds.
  • Another embodiment of the disclosure is a lipid-containing composition
  • a lipid-containing composition comprising polyunsaturated, monounsaturated, and saturated fatty acids, wherein the ratios and amounts of said three fatty acid types are controlled based on one or more of the following factors for a mammalian subject: age, sex, climate, body weight, diet, and medical conditions.
  • compositions suitable for administration to a mammalian subject comprises three or more of the following substances (or the oil thereof) in certain defined concentrations: peanuts, almonds, olives, soybeans, cashews, flaxseeds, pistachios, pumpkin seeds, sunflower seeds, sesame seeds, walnuts, anhydrous butter, and, coconut meat.
  • a safflower oil, sunflower oil, peanut oil, almond oil, and anhydrous butter oil is a specific lipid composition suitable for administration to a mammalian subject.
  • Another aspect of the present disclosure is directed at methods of prophylaxis or treatment of a medical condition for a mammalian subject, said method comprising administering a therapeutically effective amount of balanced lipid formula to said subject.
  • Yet another aspect of the present disclosure is directed at methods of creating lipid and other nutrients-balanced diet by combining special formulated lipid composition with lipid-free food.
  • prophylaxis refers to the preservation of health, a preventive treatment, or a treatment meant to reduce the risk of a medical condition.
  • treatment in the context of a medical condition refers to the management of the condition and may or may not involve the complete amelioration of the condition.
  • medical condition is a disease, disorder, syndrome, and the like; or a symptom thereof.
  • lipid imbalance refers to a suboptimal/undesirable lipid profile in blood or other tissue of a mammal, or a deficiency or excess of one or more lipids as compared with a medical norm or as indicated by the manifestation of a disorder. It is understood that the body's defense mechanisms (such as storage of essential fatty acids among others) can help compensate for a deficiency or excess of a particular fatty acid to a limited extent.
  • a “therapeutically effective amount” is an amount of a composition that results in the prophylaxis and/or treatment of a medical condition or symptom of a medical condition.
  • the adverse level of a biomarker or the severity of a symptom of the medical condition is abated at least 10% or more, at least 25% or more, at least 50% or more, at least 75% or more, or 100% ameliorated.
  • the phrase “adequate amount of omega-3” refers to a minimum of dietary reference intake (DRI) levels of omega-3 per day from foods, supplements, and/or the lipid compositions.
  • DRI dietary reference intake
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit may be achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement may be observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder.
  • the compositions may be administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
  • the present disclosure incorporates relatively high ratio of omega-6 to omega-3 fatty acid, while maintaining optimal daily delivery of both omega-6 and omega-3.
  • One reason for maintaining the high ratio is because of the incorporation of nuts and nut oils as integral components of a formulation, which nuts and nut oils have high antioxidants and phytochemical content and other properties that render excessive omega-3 unnecessary.
  • compositions comprising supplementation with one or more of following: Vitamin A, B9 (folic acid), C, D, E; Carotenoids like Beta-carotene, Lycopene, Lutein/Zeaxanthin; Flavonoids like Anthocyanidins, Catechins, Flavonoles, Flavonones, Isoflavones, Phytoestrogens including phytosterols, Quercetin, Organosulfurs, Polyphenols including curcumin, and Sulfides; melatonin; one or more anti-oxidant fatty acids such as ellagic acid and gallic acid, anti-oxidants and phytochemicals in general; and anti-oxidant trace elements Cu, Zn, Mn, Fe, Se, and Mg.
  • Vitamin A, B9 folic acid
  • C D, E
  • Carotenoids like Beta-carotene, Lycopene, Lutein/Zeaxanthin
  • Flavonoids like Anthocyanidins, Cat
  • each of these supplements/nutrients may reduce the requirement for omega-3 fatty acids and allow for a higher omega-6 to omega-3 ratio than in the absence of said supplement(s)/nutrient(s).
  • each of these nutrients is optimized through natural sources such as oils, butters, nuts and seeds, herbs, sweeteners, and other foods.
  • Nuts and seeds are plant embryos containing plant stem cells. They are made to survive the harshest of the climactic conditions until factors are suitable for germination. As such, gram per gram, they are one of the richest sources of natural nutrients. Almonds are one of the most nutritionally dense nuts, providing an array of powerful nutrients: flavonoids, vitamin E, manganese, magnesium, copper, vitamin B2 and phosphorus, to name a few. The flavonoids found in nuts, particularly almond skins, together with the vitamin E found in their meat double the antioxidants that either delivers separately.
  • Walnuts, pecans and chestnuts have the highest antioxidant content of the tree nuts, with walnuts delivering more than 20 mmol antioxidants per 3 ounces, including at least 16 antioxidant phenols, vitamin E, and ellagic and gallic acid. Walnuts are also exceptionally high in their content of the omega-6 fatty acid linoleic acid and the omega-3 fatty acid alpha-linolenic acid.
  • Peanuts also contribute significantly to dietary intake of antioxidants, rivaling the antioxidant content of blackberries and strawberries, and are far richer in antioxidants than apples, carrots or beets. Peanuts are a good source of vitamin E (gamma- and alpha-tocopherol), niacin, folate, proteins, and manganese. Peanuts also contain high concentrations of phytochemicals polyphenols, including resveratrol.
  • Sesame seeds are a very good source of manganese, copper, calcium, magnesium, iron, phosphorus, vitamin B1, zinc and dietary fiber. In addition to these important nutrients, sesame seeds contain sesamin and sesamolin, phytosterols. Sesame seeds have the highest total phytosterol content (400-413 mg per 100 grams) of all nuts and seeds; pistachios and sunflower seeds are the second richest (270-289 mg/100 g), closely followed by pumpkin seeds (265 mg/100 g).
  • a quarter cup of sunflower seeds may provide 31.9% of the daily value for magnesium.
  • Sunflower seeds are also a good source of selenium.
  • Cashews, flax seeds, pumpkin seeds, and sesame seeds are a good source of magnesium.
  • Almonds, cashews, sunflower seeds, pumpkin seeds, walnuts, and sesame seeds are a good source of copper.
  • Almonds, flaxseeds, peanuts, sunflower seeds, pumpkin seeds, and walnuts are a good source of manganese.
  • Just one-quarter cup of almonds may supply 45.0% of the daily value for manganese, and 20.0% of the daily value for copper.
  • compositions that include seeds, nuts, and/or oils.
  • the compositions include legumes, dairy, cocoa, lentils, and/or grains.
  • the composition can include one or more edible oils, culinary nuts and/or seeds in their whole form or their oils such as, but not limited to acai oil, amaranth oil, apple seed oil, apricot kernel oil, argan oil, artichoke oil, avocado oil, babassu oil, ben oil, blackcurrant seed oil, borage seed oil, borneo tallow nut oil, bottle gourd oil, buffalo gourd oil, butter oil (anhydrous), canola oil (rapeseed), cape chestnut oil, carob pod oil, cocklebur oil, cocoa butter oil, cohune oil, coriander seed oil, corn oil, cottonseed oil, dika oil, evening primrose oil, false flax oil (camelina sativa), fish oil (cod liver), fish oil (herring), fish oil (menhaden
  • compositions of the present disclosure include the following optimally balanced fatty acids and combinations thereof.
  • Saturated fatty acids butyric (C4:0), lauric (C12:0), myristic (C14:0), palmitic (C16:0), stearic (C18:0), and arachidic (20:0); monounsaturated fatty acids: myristoleic (C14:1), palmitoleic (C16:1), and omega-9 oleic (C18:1), gadoleic (C20:1), erucic (C22:1), and nervonic (C24:1); and polyunsaturated fatty acids: omega-6 linoleic (C18:2), conjugated-linoleic (C18:2), gamma-linolenic (C18:3), eicosadienoic (C20:2), di-hommo-gamma-linolenic (C20:3), and arachidonic
  • synergy among complementing nutrients from different sources may be incorporated. Furthermore, using different sources avoids concentrated delivery of specific phytochemicals that may be harmful in excess, since nuts and seeds are known to have strong positive and negative outcomes.
  • Ayurvedic principles Egyptian medicine proven empirically over centuries
  • principles around the use of oils, nuts, and seeds may be integrated with western molecular science to design various lipid-containing compositions.
  • the disclosure provides compositions that include polyunsaturated fatty acids, monounsaturated fatty acids, saturated fatty acids, including omega-3, omega-6, and omega-9 fatty acids.
  • the composition is a liquid formulation.
  • the composition is a solid formulation.
  • the composition is a semi-solid formulation.
  • the composition can substitute the unbalanced fats (cooking oils, fats, and the like) that are typically added to various food preparations and/or supplement fats contained in an individual's diet from other sources.
  • the entire diet is a composition, balanced with respect to fatty acids, antioxidants, phytochemicals, vitamins, and minerals.
  • the disclosure may further comprise herbs, spices, sweeteners, and additives.
  • the disclosure includes compositions wherein the ratios of omega-3, omega-6 and omega-9 are in an amount sufficient to prevent the onset or progression of, protect from the severity of or decrease a medical condition or disorder, or a symptom thereof.
  • the compositions described herein are formulated with respect to one or more of an individual's factors including but not limited to diet, gender, age, size, weight, medical conditions, family medical history, climate and other demographic factors.
  • the compositions may be delivered by any acceptable delivery method; in certain embodiments vitamins and minerals may be added to the compositions, and in certain embodiments, an additional vitamin and mineral supplement may be administered.
  • an individual with a herbivorous diet, an ovo-lacto vegetarian diet, a vegan diet, or a high-antioxidant high-phytochemical omnivorous diet may be administered related compositions.
  • an individual with a low-antioxidant low-phytochemical herbivorous diet, a low-antioxidant low-phytochemical ovo-lacto vegetarian diet, a low-antioxidant low-phytochemical vegan diet, or a low-antioxidant low-phytochemical omnivorous diet may be administered related compositions.
  • an individual may be administered with compositions that are formulated with respect to whether his or her diet comprises a low or high intake of seafood. This pertains to concentrated lipid compositions.
  • One method of measuring antioxidant and phytochemical consumption is to measure the number of fruits, vegetables, whole grains, and legumes servings per day, where two or more per day may provide high-antioxidant, high-phytochemical content.
  • certain herbs such as turmeric may contain potent phytochemicals (even in small quantities, e.g., a quarter-teaspoon)
  • the disclosure provides a number of different compositions, including one with varying levels of omega-3 to suit a consumer's diet and/or tolerance level.
  • “tolerance” and the like means the ability of a consumer to withstand the composition without any discomfort.
  • the compositions designed for consumers with high seafood diet include low amount of nuts and seeds. In some instances, no nuts or seeds.
  • Other phytochemicals may also be minimized or eliminated as part of a composition to avoid unfavorable interactions.
  • compositions comprising the lipid formulation disclosed herein may be administered to an individual in any orally accepted form.
  • the lipid formulations may be packaged in one, two, three, four or more mutually complementing daily dosages. In some embodiments, they may be contained in any one or more of, but not limited to, a single dosage or sustained and controlled release capsule, soft-gel capsule, hard capsule, tablet, powder, lozenge, or pill prepared in some instances with carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like; a powder or a granule; a nutritional bar; a bakery food product such as a bread, a dessert, a pastry, a truffle, a pudding or cake; a sealed single dosage packet or resealable packaging containing a liquid, an oil blend, a gel, a sauce, a dressing, a spread, a butter, drops, a semi-solid; liquid, or the like; or
  • compositions may be unsealed and taken orally, or added as part of a cooking ingredient to previously cooked or uncooked food preparation with or without added fat.
  • they can be made into special cooking oil, butter, dressing, etc. and be added into foods while such foods are being prepared.
  • the components of the compositions may be delivered in one-part or multiple parts as various components of a meal or to complement a meal, for example.
  • the lipid-containing compositions may be delivered using a gelatinous case, a vial, a pouch or a foil for containing such compositions.
  • they may be part of an enteral or parenteral formula, or a combination thereof.
  • a one-day, one-week, two-week, bi-weekly, bimonthly, or monthly diet plan may be formulated comprising various lipid formulations described herein, with varying compositions administered each day.
  • the balanced lipid composition disclosed herein may be used to create a completely balanced diet plan, by adding the composition, which contains balanced components of lipids, phytochemicals, antioxidants, vitamins, to name a few, into foods as a dietary component.
  • a dietary component can be a cooking ingredient added to prepared or unprepared food or beverage. In some embodiments, it can also be a finished food product such as a dessert or side dish, which are served together with other components of a meal.
  • Special foods containing no lipid or low lipids for example small amounts of lipids contained in meats, poultry, seafood, milk, fruits, vegetables, and grains
  • the administration of the balanced composite nutrients may be achieved through one course in a meal or multiple courses in a meal (e.g., salad, main course, and dessert).
  • Each individual may be given instructions on use of the product, and risk and cautionary measures, as is usual with any pharmaceutical, nutraceutical, or any product intended for ingestion. Oils, nuts, seeds, and herbs are potent; therefore, instructions may include recommended dosage, frequency, and suggestions for optimization.
  • the delivery of the desired lipid composition may be achieved through a one-part or multi-part delivery system.
  • the desired formulation may be achieved through adding various components to various parts of a meal, including bread, salad, main course, and/or dessert.
  • One aspect of the disclosure is to deliver fatty acids in such a way that the total daily delivery of omega-6 and omega-3 from the lipid composition and the rest of the diet are optimal with respect to daily recommendations.
  • Yet another aspect of the present disclosure is the concept of steady delivery of fatty acids, based on the observation that each time there is a change in dietary lipid composition, it upsets the body physiology, sometimes with adverse effects such as headaches, muscle and joint pains, digestive and bowel upset, mental confusion, and anxiety; and at other times it may cause short-lived euphoria and general sense of wellness. Though the body adapts to the change in 2-3 weeks or longer, long-term effects of the change outside the optimal range may be harmful. Furthermore, sudden large fluctuations in fatty acids can also have acute adverse effects. This steady delivery requires a steady dosage within the optimal range lasting approximately 2 to 3 weeks at a minimum.
  • the formulations described herein have high antioxidant and phytochemical content and properties that render extra omega-3 unnecessary.
  • sterols, sweeteners (such as honey), and herbs/spices (such as curcumin) included in the compositions can render extra omega-3 unnecessary.
  • the formulations may provide a balanced fatty acid composition of approximately 10-100 grams of total daily fat.
  • the formulations may include specific ratios of various lipid components as shown below in Table 3. The ratios may be weight by weight, weight by volume, or volume by volume (w/w, w/v, or v/v).
  • the lipid formulation calls for specific percentages of omega-9, omega-6, and omega-3 fatty acids, as shown in Table 4 below.
  • compositions of the disclosure are formulated as per climatic condition and ambient temperature range.
  • Table 5 provides % by weight ranges for a lipid formulation that includes oils, nuts and seeds as disclosed by embodiments of the present disclosure, by climatic condition and temperature range.
  • Table 6 provides % by weight ranges (% of weight of the entire composition) for omega-9, omega-6, and omega-3 fatty acids as disclosed by embodiments of the present disclosure, by climatic condition and temperature range.
  • compositions were prepared for healthy individuals living in a variety of climates, with a high antioxidant/phytochemical diet and/or a vegetarian diet, for maintenance of general health and well-being.
  • the compositions were made up of a variety of oils, nuts and seeds, as described below.
  • the compositions as presented in the tables below were formulated by three different methods: lipid liquid formulation only, a solid or semi-solid nut and seed formulation only, or a combination formulation containing oils, nuts and seeds.
  • the compositions were formulated to be administered in a once a day format (combined formulation), or a twice a day format where one administration was of the liquid lipid formation and the other administration was of the solid nut and seed composition.
  • Table 7 provides the omega-6 to omega-3 ratio contained in the lipid compositions of this example for a range of climates. The ratios are presented, for any one of the liquid only, solid only, or combination formulations.
  • Table 8 provides the ratio of total lipids to each of monounsaturated, polyunsaturated, and saturated fatty acids in the lipid compositions of this example, for a range of climates. The ratios are presented, for any one of the liquid only, solid only, or combination formulations.
  • One aspect of the disclosure is to supply lipid formulation tailored to different human subjects based on their age and sex, and diet.
  • Table 9 below provides dose ranges for total fat content in grams, the ratio range of monounsaturated fat to polyunsaturated fat, and the ratio range of monounsaturated fat to saturated fat, range of omega-6 content in grams, ratio range of omega-9 to omega-6, range of omega-3 content in grams, and the ratio range of omega-6 to omega-3 for vegetarian or high antioxidant and/or high phytochemical consuming non-vegetarian subjects as disclosed by embodiments of the present disclosure, by gender and age group.
  • Table 10 provides dose ranges for total fat content in grams, the ratio range of monounsaturated fat to polyunsaturated fat, and the ratio range of monounsaturated fat to saturated fat, range of omega-6 content in grams, ratio range of omega-9 to omega-6, range of omega-3 content in grams, and the ratio range of omega-6 to omega-3 for non-vegetarian (i.e., omnivorous) or low-antioxidant and/or low phytochemicals consuming vegetarian subjects as disclosed by the present disclosure by gender and age group.
  • non-vegetarian i.e., omnivorous
  • low-antioxidant and/or low phytochemicals consuming vegetarian subjects as disclosed by the present disclosure by gender and age group.
  • Table 11 provides dose ranges for total fat content in grams, the ratio range of mono-unsaturated fat to polyunsaturated fat, and the ratio range of monounsaturated fat to saturated fat, range of omega-6 content in grams, ratio range of omega-9 to omega-6, range of omega-3 content in grams and the ratio range of omega-6 to omega-3 for high-seafood consumers as disclosed by the present disclosure by gender and age group.
  • the total daily lipids from all foods are within the ratios described herein and the compositions described herein are administered to an individual that falls within the age and calorie intake range as recommended.
  • the lipid ratios and compositions described herein are administered to an individual whose total diet comprises 20%-45% of calories from fat (including from the lipid compositions), 45%-65% calories from carbohydrates, and 10%-25% calories from proteins.
  • the total calories consumed by the individual falls within the ranges as daily recommended average, as per gender, age, and activity level, to name a few.
  • a meal plan may be established for the subject to be followed in conjunction with the administration of the composition.
  • the lipid ratios and compositions described herein are administered to an individual whose diet comprises 20%-45% of calories from fat. In one aspect 60-90% of calories from fat are supplied by the lipid compositions described herein. In a further aspect the calories from fats are supplied by one or more of fish oils, dairy products (butter, butter oil, milk, milk cream, and/or cheese), fruit oils, vegetable oils, nuts, seeds, nut oils, and seed oils.
  • the lipid ratios and compositions described herein are administered to an individual whose diet comprises 45%-65% of total calories from carbohydrates.
  • the diet comprises 45%-65% of total calories from carbohydrates, which carbohydrates are from a 50%-70% intake of grains in calories, 15%-30% intake of vegetables in calories, and 10%-30% intake of fruits in calories.
  • the calories from carbohydrates are additionally from one or more of spices, sweeteners, and beverages.
  • the 50%-70% of carbohydrates from grains are supplied by one or more of wheat, rice, corn, barley, spelt, oats, rye, buckwheat, millet, quinoa, and other grains.
  • the lipid ratios and compositions described herein are administered to an individual whose diet comprises 10%-25% of calories from proteins.
  • the diet comprises 10%-25% of calories from proteins, which proteins are from one or more of but not limited to legumes, eggs, cheese, milk, yogurt, poultry, seafood, and meat.
  • a diet plan which includes the 25%-45% of calories from fat, which are supplied by the lipid compositions described herein.
  • a 1-day, a 1-week, a 2-week, or a 1-month diet plan is provided which includes the 20%-45% of calories from fat, of which 60-90% of fat calories are supplied by the lipid compositions described herein.
  • the remaining 45-65% of calories from carbohydrates and 10-25% of calories from proteins are supplied by a diet including the following components, ranges specified in calories.
  • Table 12 provides dose ranges for total fat content in grams, the ratio range of monounsaturated fat to polyunsaturated fat, and the ratio range of monounsaturated fat to saturated fat, range of omega-6 content in grams, ratio range of omega-9 to omega-6, ratio range of omega-6 to omega-3, range of omega-3 content in grams designed by age and gender with increasing strength of omega-3, low, medium, and high, such that the human subject may choose the composition most agreeable to his/her diet, where the selection may be based upon the level of antioxidants and phytochemicals in the diet and/or medical predisposition.
  • lipid compositions described herein are administered to an individual for the prophylaxis and/or treatment of diseases, disorders or conditions.
  • the lipid formulation is used to alleviate symptoms of menopause, the process of the cessation of menstruation. It is also used to alleviate the symptoms of endocrine disorders.
  • Table 13 provides dose ranges for total fat content in grams, the ratio range of monounsaturated fat to polyunsaturated fat, and the ratio range of monounsaturated fat to saturated fat, range of omega-6 content in grams, ratio range of omega-9 to omega-6, range of omega-3 content in grams, and the ratio range of omega-6 to omega-3 for subjects with medical indications as disclosed by the present disclosure.
  • lipid composition parameters were established per diet or medical condition, intended for daily administration (one or more components).
  • the parameters of the compositions were established for an individual whose diet is high in antioxidants/phytochemicals and/or is a vegetarian; an individual whose diet is low in antioxidants/phytochemicals and/or is a non-vegetarian, or an individual presenting with a medical condition or disorder.
  • the compositions are made up of a variety of nut oils, seed oils, vegetable oils, fruit oils, and other oils, nuts, and seeds.
  • Table 14 presents the ratio ranges of polyunsaturated, monounsaturated, saturated, omega-3, omega-6, and omega-9 fats.
  • Table 15 presents some composition with the specified ratios of polyunsaturated, monounsaturated, saturated, omega-3, omega-6, and omega-9 fats.
  • liquid lipid and solid lipid composition parameters were established per diet or medical condition, intended for twice-a-day administration (i.e. 2 component daily formulation).
  • the parameters of the compositions were established for an individual whose diet is high in antioxidants/phytochemicals and/or is a vegetarian; an individual whose diet is low in antioxidants/phytochemicals and/or is a non-vegetarian, or an individual presenting with a medical condition or disorder.
  • the compositions are made up of a variety of nut oils, seed oils, vegetable oils, fruit oils, and other oils, nuts, and seeds.
  • Table 16 presents the ratios of polyunsaturated, monounsaturated, saturated, omega-3, omega-6, and omega-9 fats for the bar (solid) formulation.
  • Table 17 presents the ratios of polyunsaturated, monounsaturated, saturated, omega-3, omega-6, and omega-9 fats for the liquid formulation.
  • Table 18 presents examples of bar formulation (solid) and
  • Table 19 presents one liquid composition with the specified ratio ranges of polyunsaturated, monounsaturated, saturated, omega-3, omega-6, and omega-9 fats.
  • one liquid lipid composition parameters was established and one formulation was prepared, intended for once, twice, or thrice or more a day administration to an individual whose diet is high in antioxidants/phytochemicals and/or is a vegetarian and to an individual who does not favor, or cannot tolerate nuts and seeds.
  • the compositions include a variety of nut oils, seed oils, vegetable oils, fruit oils, and other oils. Some ranges for a formulation are provided by % by weight (w/w) for each component (representing the % weight for that individual component on a daily basis).
  • the compositions can be administered once or more daily.
  • compositions may include two or more of: almond oil (4%-23%), anhydrous butter oil (5%-29%), avocado oil (1%-6%), cashew oil (2%-15%), coconut oil (0%-2%), corn oil (3%-19%), fish oil (0%-5%), flaxseed oil (0%-5%), mustard oil (0%-5%), olive oil (3%-17%), palm oil (0%-5%), peanut oil (5%-30%), pistachio oil (1%-7%), pumpkin seeds (1%-8%), safflower oil (high oleic) (1%-5%), sesame oil (0%-50%), soybean lecithin (0%-5%), soybean oil (1%-7%), sunflower oil (high oleic) (2%-14%), sunflower oil (regular) (0%-5%), and/or walnut oil (3%-15%).
  • compositions included a variety of nut oils, seed oils, vegetable oils, fruit oils, and other oils. Some ranges for a formulation are provided by % by weight (w/w) for each component (representing the % weight for that individual component on a daily basis). The ranges can accommodate vegetarian/high-antioxidant/high-phytochemical user and omnivore/low-antioxidant/low-phytochemical user or a seafood user, in different combinations.
  • the compositions can be administered once or more daily.
  • compositions may include two or more of: almond oil (2%-36%), anhydrous butter oil (2%-36%), coconut oil (0%-8%), corn oil (1%-24%), flaxseed oil (0%-8%), mustard oil (0%-8%), olive oil (2%-36), palm oil (0%-2%), peanut oil (4%-72%), pumpkin seeds oil (1%-24%), safflower oil (high oleic) (2%-60%), soybean lecithin (0%-4%), sunflower oil (high oleic) (4%-72%), and/or walnut oil (2%-36%).
  • Liquid lipid and solid lipid composition parameters were established for a twice-daily administration (i.e. 2-component daily formulations).
  • the compositions were made up of a variety of nut oils, seed oils, vegetable oils, fruit oils, and other oils.
  • the ranges for each component of the liquid and solid formulations are presented for each of the solid and liquid formulations.
  • the solid formulation includes two or more of by % weight of total composition: almonds (10%-25%), cashews (7%-15%) coconut shredded (1%-4%), flaxseed (0%-1%), olives (15%-25%), peanuts (4%-15%), pistachios (2%-9%), pumpkin seeds (2%-12%), sesame (0%-0%), soybeans (8%-20%), sunflower seeds (1%-4%), and/or walnuts (5%-15%).
  • the liquid formulation includes two or more of by % weight of total composition: avocado oil (3%-14%), corn oil (15%-30%), mustard oil (0%-2%), olive oil (10%-22%), palm oil (0%-2%), peanut oil (15%-35%), safflower oil (high oleic) (5%-15%), soybean lecithin (0%-2%), sunflower oil (high oleic) (10%-25%), and/or anhydrous butter oil (5%-15%).
  • compositions were made up of a variety of nuts, seeds, nut oils, seed oils, vegetable oils, fruit oils, and other oils. The ranges for each component of the formulations are presented for each of the solid and liquid components.
  • the formulation can include two or more of by % weight of total composition: peanuts or peanut oil (4-35), almonds or almond oil (2%-25%), olives or olive oil (3%-45%), legumes or grains (15%-45%), cashews or cashew oil (10%-40%), pistachios or pistachio oil (5%-25%), pumpkin seeds or pumpkin seed oil (4%-25%), sunflower seeds or sunflower seed oil (2%-30%), sesame seeds or sesame seed oil (0%-20%), walnuts or walnut oil (5%-25%), flaxseed or flaxseed oil (0%-10%), anhydrous butter oil or milk product including cheese (5%-45%), coconut meat or coconut oil (2%-8%), corn oil (3%-20%), avocado oil (3%-8%), safflower oil (2%-20%), mustard oil (0%-8%), palm oil (0%-8%), and/or soybean lecithin (0%-2%).
  • Example 10 A 47-year old female presented with menopause-related hot flushes.
  • the subject's diet was supplemented with a combination of vegetable oils, seed oils, nuts and seeds for a period of 6 weeks.
  • the subject was provided with the twice-daily administration formulation in Example 10.
  • Nutrients from the total diet (natural sources) including the lipid composition administered were as follows in Table 20.
  • the host subject experienced hypercholesterolemia on a vegetarian diet low in fat, mostly olive oil (75% monounsaturated fat), a daily fish oil supplement of 1 gram, and a daily total essential fatty acids (EFA) supplement of 1 gram.
  • EFA essential fatty acids
  • the subject was then administered a daily lipid composition supplement containing 11 grams of omega-6 and 1.2 grams of omega-3, made up primarily from a combination of vegetable oils, and nuts and seeds.
  • Administration of the lipid composition resulted in a reduction of LDL from 160 mg to 120 mg.
  • omega-6 In another human subject, intense muscle spasms arising from the left thoracic cavity/wall were observed subsequent to a meal high in omega-6, whereas the subject's typical diet included primarily monounsaturated fatty acids and very small amounts of saturated fatty acids. It is hypothesized, that sudden increase in omega-6, when the body is chronically deficient may be harmful.
  • Polyunsaturated fats (omega-6, particularly gamma-linolenic acid) have often been recommended to reduce coronary heart disease along with recommendations to reduce saturated fatty acids. But all saturated fats do not have the same effect on cholesterol synthesis in the liver. Saturated fats of chain-length 12, 14 and 16 (lauric acid, myristic acid and palmitic acid) have been shown to elevate blood cholesterol. Stearic acid (18-carbon, saturated) has been shown to lower cholesterol by 21%—even more than oleic acid (18-carbon, monounsaturated), which lowers LDL by 15%. Polyunsaturated fats increase cell membrane fluidity and therefore tissue flexibility, including that of the arteries.
  • omega-6 and omega-3 The subject host was placed on a trial of varying ratios of omega-6 and omega-3 using various oils and nut combinations. Each time omega-3 was reduced or omega-6 was increased the subject became depressed and was given to crying at the slightest provocation. When omega-3 was increased, it elevated the subject's mood, immediately noticeable. However, within certain ranges of omega-6 and omega-3, the effect was self-adjusting, e.g., over a period of 3-6 weeks the moods normalized. It was also observed that within that range of omega-6 and omega-3, over a period of 3-6 weeks the subject in fact was more grounded at higher levels of omega-6; and was euphoric at higher levels of omega-3. Omega-3 increase enhanced cognitive function, which was immediately noticeable.
  • Omega-3 reduction caused confusion, dyslexia, and a decline in cognitive function but these symptoms subsided with time, again within certain omega-6 and omega-3 ranges.
  • the subject also displayed greater attention span and concentration after omega-6 and omega-3 were optimized over a period of 3-6 weeks, with greater reading speeds and comprehension.
  • the subject performed better at a lower level of omega-3, which suggests that an adaptation mechanism was activated to compensate for the required level of omega-6 metabolites.
  • Manipulation of dietary fats can alter the fatty acid composition of brain-cell membranes, with effects on thought processing and behavior.
  • Polyunsaturated fatty acids could be associated at different levels in the pathophysiology of major depression, on one hand through their role in the membrane fluidity which influences diverse steps of neurotransmission and, on the other hand, through their function as precursors of pro-inflammatory cytokines and eicosanoids disturbing neurotransmission.
  • the subject host was a 50-year old woman whose symptoms included dental sensitivity, deteriorating muscle mass, occasional breathing difficulty, easy bruising, mild arrhythmia, and difficult bowel movement.
  • a dentist as a solution to her sensitive teeth, had extracted and replaced her teeth with dentures at 50.
  • Each of her other symptoms was treated as a stand-alone symptom and treated with non-lipid medications.
  • At 60 she developed loss of balance, diplopia (double vision), and slurry speech.
  • PSP Progressive Supra-nuclear Palsy
  • the subject then lost ambulation and speech, and developed dysphagia. She passed away at 67 from pneumonia.
  • omega-6 is also evident from her early symptoms: muscle mass requires a balance of omega-6 and omega-3, lack of omega-6-derivative leukotrienes would lead to asthma-like breathing issues (conversely excessive leukotrienes can also lead to asthma like symptoms), deficiency of omega-3 has been linked with arrhythmia, and deficiency of omega-6 derived thromboxanes would lead to easy bruising, and lack of omega-6 derived prostaglandins will impede smooth muscle activity and therefore the bowel movement.
  • the fact that she was post-menopausal made the requirement of omega-6 and omega-3 more critical, since estrogen and androgens, as hypothesized in the present disclosure, have similar actions and benefits as polyunsaturated fats. When the reproductive hormones decline, the body increasingly depends on omega-6 and omega-3 for the physiological functions.
  • LA metabolite Arachidonic acid (AA) and ALA metabolite docosahexaenoic acid (DHA), that are so abundantly present in neural tissue, particularly the membranes of neural synapses, may have caused the neurodgeneration.
  • Neuroinflammation is a host defense mechanism associated with neutralization of an insult and restoration of normal structure and function of brain, and is characteristic of all major neural diseases.
  • the dietary deficiency of LA and ALA, and the resulting unfavorable tissue ratio of AA to DHA might have affected the neurodegeneration associated with acute neural trauma and neurodegenerative disease.
  • omega-6 or omega-3 deficiencies or imbalance lead to PSP. It simply creates a distress in the body; the disease developed depends on rest of the body chemistry. In the Western world omega-3 has received much attention because of the populace's consumption was highly skewed towards omega-6 and that with inadequate antioxidant and phytochemical intake. Requirement of omega-3 is very small, and increases only with the increase in omega-6. Disclosed herein are methods and compositions to balance omega-3 and omega-6, in light of demographic factors, and for their steady delivery.
  • the subject was a vegetarian woman in her mid-30s, on a low fat diet using primarily olive oil and nuts. She had developed Amyotrophic Lateral Sclerosis (ALS)-like symptoms: muscle weakness in hands, arms, legs, and the muscles of speech, twitching and cramping of muscles, shortness of breath, and difficulty in swallowing. The left side of her body was affected more than the right side. Upon administration of a lipid composition and changes in diet that increased omega-6 to about 12 grams, her symptoms disappeared and the muscle tone improved, better than before the onset of symptoms. It is hypothesized that in this instance, the amount of omega-3 relative to omega-6 in the tissue had exceeded the ratio tolerated by the body. Since the vegetarian diet and nuts contributed plenty of antioxidants and phytochemicals, the subject became deficient in omega-6, despite moderate levels of omega-3.
  • ALS Amyotrophic Lateral Sclerosis
  • ALS slurred speech
  • ALS is known to remit or halt its progression, though there is no scientific understanding as to how and why this happens.
  • the inventor hypothesizes that it has to do with inadvertent change in omega-6 and omega-3 fatty acids. Most of us fall into certain food patterns based on likes and dislikes, habits inherited from family, accessibility of certain foods, cooking habits, and the foods that happen to be in vogue.
  • omega-6 and omega-3 therapy by administration of lipid compositions. Increases in omega-3 beyond 0.5 g, in a vegetarian host with omega-6 at 10-11 grams, yielded better muscular performance, lesser joint pain, lesser joint crackling sounds, and better spatial task performance. But a point of diminishing marginal returns was reached at about 1.2 grams of omega-3. Increases of omega-3 beyond 1.2 grams resulted in weaker muscle tone, posture, and exercise endurance. When the omega-3 was gradually brought back to 1.2 grams, the subject experienced leg cramps, lower back pain, burning sensation in the scalp, buckling of knee joints, and joint pains in knees and shoulders. Over a period of 3-6 weeks these symptoms subsided.
  • Gout a joint disorder, on a low-fat diet, primarily olive oil, and nuts. The symptoms disappeared upon increase of omega-6 in the diet.
  • TOS Myofascial Pain Syndrome
  • TOS Thoracic Outlet Syndrome
  • MFS Myofascial Pain Syndrome
  • TOS Thoracic Outlet Syndrome
  • the host subject went through numerous examinations including: MRIs of the entire CNS, X-rays, blood work, drug therapies, massage therapies, and chiropractic treatment. The symptoms would go away and then reappear a few months or a year later.
  • omega-6 and omega-3 in the subject's diet by administration of lipid compositions the episodes of TOS and myofascial pains subsided. It is hypothesized herein that these episodes were the result of the body being severely deficient in omega-6 and omega-3.
  • omega-6 and omega-3 which can occur by any incidental changes in diet, there was a sudden surge in prostaglandins, thromboxanes, and leukotrienes, resulting in severe muscular tightening.
  • Other mechanisms related to the lipids may be involved that are not yet understood.
  • Varying quantities and ratios of omega-6 and omega-3 were administered on otherwise healthy subjects to see if very early symptoms of diabetes could be induced.
  • High blood sugar, excessive urine production, excessive thirst and increased fluid intake, blurred vision, unexplained weight gain and lethargy were induced by certain ratios of omega-6 and omega-3 fatty acids.
  • These simulated symptoms with very high levels of omega-3 may also be reversed by reducing the dosage.
  • insulin resistance may be associated with low levels of omega-6 fatty acids.
  • omega-6 In the host subject, incidences of acid reflux disease, irritable bowels, indigestion, and dyspepsia were observed. Each time omega-6 was increased or omega-3 was decreased the following symptoms appeared: stomach pain, bloating, heartburn, nausea (upset stomach), and burping; but they all disappeared as the body adjusted to increased omega-6. Omega-6 was tested up to 11 grams. It is hypothesized that beyond that point in the particular host the symptoms would persist. Increasing omega-3 beyond 2 grams caused tight dark pellet-like stools. In the optimal omega-6 and omega-3 balance, bile production was optimal as determined by the yellowish brown color of the stools.
  • mucus production in the alimentary canal was optimal with the proper omega-6 and omega-3 quantities and ratio, using mucus production in the oral cavity as an indicator.
  • Halitosis was also observed with 2 grams of omega-3, and got worse when omega-3 was reduced, and then normalized over a period of 3-6 weeks.
  • Arachidonic acid plays a pivotal role in protection and integrity of the intestinal mucosa. Excessive omega-3 can displace arachidonic acid leading to gastro-intestinal mucosal damage.
  • Dietary fatty acids are intricately linked with reproduction from menstruation, to fertilization, to gestation-related complications such as diabetes, to development of the fetus, to pre-term delivery, to post-natal health of the mother and the child.
  • omega-6 and omega-3 fatty acids including muscle mass restoration, stabilizing sleep, increasing mental sharpness, increasing energy and vigor, improved skin, reduction in hair loss, improving bowel function, improving libido and sexual function, and weight management.
  • the management of frequent urination with the ideal balance of omega-6 and omega-3 was also observed. It is hypothesized that this is due to combined effect of management of omega-6 and omega-3 related eicosanoids and their effect on physiological functions, and due to the sex-hormone-like effect of these lipids, and due to their effect on the optimization of sex hormone production.
  • the present disclosure also provides compositions and methods for tissue repair and/or regeneration by induction and maintenance of endogenous stem cell proliferation and/or differentiation including by providing the environment for the stem cells to proliferation and/or differentiate.
  • the fibroblast is a type of cell that synthesizes the extra-cellular matrix and collagen, the structural framework for animal tissues. Proper fibroblast function is essential for optimal tissue repair and regeneration.
  • Polyunsaturated fatty acids and sterols create a favorable fibroblast plasma membrane environment, and are believed to play a role in electrochemical gradient across the bilayer-lipid membrane.
  • Schroeder F, Kier A B, Sweet W D Role of polyunsaturated fatty acids and lipid peroxidation in LM fibroblast plasma membrane transbilayer structure. Arch Biochem Biophys.
  • omega-6 and omega-3-derived leukotrienes are very important agents in lung function.
  • Docosahexaenoic acid (omega-3) is an important component of retinal photoreceptors and brain synaptic membranes, and arachidonic acid (omega-6) is an important component of vascular endothelial cells.
  • arachidonic acid (omega-6) is an important component of vascular endothelial cells.
  • omega-6 since omega-6 also has a role in vascular blood pressure, both omega-6 and omega-3 are critical to optic health.
  • omega-3, and formulations of vitamins C, E, beta-carotene, and zinc have been shown to be preventative in progression of age-related macular degeneration (AMD); increased intakes of lutein/xeaxanthin and omega-3 fatty acids are associated with progression of AMD, whereas lower intakes lutein/xeaxanthin and omega-3 are associated with greater optic health; suggesting the role of phytochemicals, and the importance of dosage.
  • Omega-6 metabolite PGD2 is believed to be a strong sleep-inducing agent, with a strong rebound of wakefulness reaching insomnia.
  • omega-3-deficient diet has been shown to lessen the pineal melatonin rhythm, weaken the endogenous functioning of the circadian clock, and to play a role in nocturnal sleep disturbances.
  • palmitoleic and oleic acid have been shown to be important for sleep disorders, perhaps due to their function as precursors of the sleep inducing oleamide.
  • the total percent by weight of any combination of components does not exceed 100%. It is also understood that if a component is present in a composition, then the component is present in a non-zero amount (for example, more than about 0.00000001) mg or percent by weight of total weight).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
US12/426,034 2008-04-21 2009-04-17 Lipid-containing compositions and methods of use thereof Abandoned US20090264520A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
US12/426,034 US20090264520A1 (en) 2008-04-21 2009-04-17 Lipid-containing compositions and methods of use thereof
BRPI0910852A BRPI0910852A2 (pt) 2008-04-21 2009-04-20 composições contendo lipídios e métodos de uso das mesmas
CN2009801232357A CN102065699A (zh) 2008-04-21 2009-04-20 含脂质组合物及其使用方法
NZ602820A NZ602820A (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
EP17182663.9A EP3305083A1 (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
PCT/US2009/041114 WO2009131939A2 (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
KR1020107026029A KR102030851B1 (ko) 2008-04-21 2009-04-20 지질을 함유하는 조성물 및 그것의 사용 방법
AU2009239499A AU2009239499C1 (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
EP09735962.4A EP2278885A4 (en) 2008-04-21 2009-04-20 COMPOSITIONS CONTAINING LIPIDS AND METHODS OF USE
JP2011506377A JP2011518223A (ja) 2008-04-21 2009-04-20 脂質含有組成物およびその使用方法
MX2010011544A MX2010011544A (es) 2008-04-21 2009-04-20 Composiciones que contienen lipidos y metodos para utilizar las mismas.
MYPI2010004944A MY157040A (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
NZ589357A NZ589357A (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
CA2759551A CA2759551C (en) 2008-04-21 2009-04-20 Lipid-containing compositions and methods of use thereof
EA201071206A EA201071206A1 (ru) 2008-04-21 2009-04-20 Композиции, содержащие липид, и способы их применения
KR1020177033162A KR102038118B1 (ko) 2008-04-21 2009-04-20 지질을 함유하는 조성물 및 그것의 사용 방법
MX2019010738A MX2019010738A (es) 2008-04-21 2010-10-20 Composiciones que contienen lipidos y metodos para utilizar las mismas.
IL208858A IL208858A (en) 2008-04-21 2010-10-21 Formulations containing fats, methods of selecting and manufacturing and using them
ZA2010/08232A ZA201008232B (en) 2008-04-21 2010-11-17 Lipid-containing compositions and methods of use thereof
CO10145300A CO6321198A2 (es) 2008-04-21 2010-11-19 Planes de dieta personalizados y suplementos alimenticios que comprenden acidos grasosomega-3 y omega-6
US13/332,251 US10292958B2 (en) 2008-04-21 2011-12-20 Lipid-containing compositions and methods of use thereof
JP2014099072A JP7007010B2 (ja) 2008-04-21 2014-05-12 脂質含有組成物およびその使用方法
JP2017216717A JP2018064563A (ja) 2008-04-21 2017-11-09 脂質含有組成物およびその使用方法
JP2020019671A JP6879597B2 (ja) 2008-04-21 2020-02-07 脂質含有組成物およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4674708P 2008-04-21 2008-04-21
US7570808P 2008-06-25 2008-06-25
US11159308P 2008-11-05 2008-11-05
US12/426,034 US20090264520A1 (en) 2008-04-21 2009-04-17 Lipid-containing compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/332,251 Division US10292958B2 (en) 2008-04-21 2011-12-20 Lipid-containing compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
US20090264520A1 true US20090264520A1 (en) 2009-10-22

Family

ID=41201653

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/426,034 Abandoned US20090264520A1 (en) 2008-04-21 2009-04-17 Lipid-containing compositions and methods of use thereof
US13/332,251 Active US10292958B2 (en) 2008-04-21 2011-12-20 Lipid-containing compositions and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/332,251 Active US10292958B2 (en) 2008-04-21 2011-12-20 Lipid-containing compositions and methods of use thereof

Country Status (15)

Country Link
US (2) US20090264520A1 (ru)
EP (2) EP3305083A1 (ru)
JP (4) JP2011518223A (ru)
KR (2) KR102030851B1 (ru)
CN (1) CN102065699A (ru)
AU (1) AU2009239499C1 (ru)
BR (1) BRPI0910852A2 (ru)
CA (1) CA2759551C (ru)
CO (1) CO6321198A2 (ru)
EA (1) EA201071206A1 (ru)
IL (1) IL208858A (ru)
MX (2) MX2010011544A (ru)
MY (1) MY157040A (ru)
WO (1) WO2009131939A2 (ru)
ZA (1) ZA201008232B (ru)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011080580A3 (es) * 2009-12-30 2011-08-25 Team Foods Colombia S.A. Esparcible con bajo contenido de grasa total hecho con aceites vegetales y fitoesteroles
WO2011113128A1 (pt) * 2010-03-18 2011-09-22 Leitao De Vasconcelos Paulo Roberto Preparados a base de óleos de vegetais e peixes usados como suplemento nutricional
WO2012135498A3 (en) * 2011-03-29 2013-04-04 Dr. Baker Says, Inc. Nutritional supplement comprising nut and seed oil composition
CN103404613A (zh) * 2013-08-22 2013-11-27 宁夏吴忠市国海粮油有限公司 一种葵花调和油及其加工工艺
US20140065279A1 (en) * 2012-09-06 2014-03-06 Michael Roizen Edible oils for frying and cooking foods having health benefits
EP2716167A1 (en) * 2012-10-02 2014-04-09 Lunamed AG Non-pharmaceutical composition comprising short chain fatty acids
ES2528331A1 (es) * 2013-08-06 2015-02-06 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta Del Hierro Composición con efecto en la salud ósea y cardiovascular
US9011949B2 (en) 2011-07-12 2015-04-21 Impossible Foods Inc. Methods and compositions for consumables
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20160219921A1 (en) * 2015-02-04 2016-08-04 Natalja Klein Super food beverage
CN106819153A (zh) * 2015-12-04 2017-06-13 金士力佳友(天津)有限公司 一种含美藤果油和深海鱼油的调和油及其应用
US9700067B2 (en) 2011-07-12 2017-07-11 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9808029B2 (en) 2011-07-12 2017-11-07 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9826772B2 (en) 2013-01-11 2017-11-28 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
EP2584920B1 (en) 2010-06-28 2017-12-13 Nestec S.A. Hypocaloric, high protein nutritional compositions and methods of using same
US20170360073A1 (en) * 2014-11-07 2017-12-21 Jolly Mathew Vadakkemuri Optimized nutrient fatty acid composition
US10039306B2 (en) 2012-03-16 2018-08-07 Impossible Foods Inc. Methods and compositions for consumables
EP3247224A4 (en) * 2014-09-01 2018-08-15 Vadakkemuri, Mathew Jolly Optimized nutrient food
EP3420822A1 (en) * 2017-06-23 2019-01-02 OliVita AS Combination of oils
US10172380B2 (en) 2014-03-31 2019-01-08 Impossible Foods Inc. Ground meat replicas
US10986848B2 (en) 2013-01-11 2021-04-27 Impossible Foods Inc. Methods and compositions for consumables
EP3876741A4 (en) * 2018-11-09 2022-08-31 L-Nutra NUTRIENT BAR FOR INTERMITTENT FASTING SIMULATE
CN116421666A (zh) * 2023-04-07 2023-07-14 云南德彩堂生物医药科技有限公司 一种稳定高效抗骨质疏松的油脂组合物，其制备方法及应用
US11854684B2 (en) 2020-12-29 2023-12-26 Kpn Innovations, Llc. Methods and systems for nourishment refinement using psychiatric markers

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264520A1 (en) 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
EP2215913A1 (en) 2009-01-23 2010-08-11 Nutreco Nederland B.V. Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed
FR2948025B1 (fr) 2009-07-15 2013-01-11 Univ Grenoble 1 Composition comprenant un polyphenol et un acide gras omega-3
CA2814053C (en) * 2010-10-14 2020-11-17 Asha Nutrition Sciences, Inc. Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof
JP2013001666A (ja) * 2011-06-14 2013-01-07 Yasuharu Omura 栄養剤組成物
CN102550710A (zh) * 2011-11-23 2012-07-11 阳泉市万和油脂有限公司 一种核桃优配油
MX364220B (es) 2012-02-09 2019-04-16 Nogra Pharma Ltd Metodos de tratamientos de fibrosis.
US20140087011A1 (en) * 2012-05-16 2014-03-27 Louise M. Smith RyWhe / The Drink of Life
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
CN102845539A (zh) * 2012-09-19 2013-01-02 河南茗轩食品科技有限公司 一种亚麻膳食调和油及其制备方法
TN2013000036A1 (fr) * 2013-01-29 2014-06-25 Guetari Sami Complement alimentaire omega 3 a base d'huile de poisson ameliore
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
SG10201707324WA (en) * 2013-03-12 2017-10-30 Hmi Inc Plant extracts with anti-diabetic and other useful activities
CN103156195B (zh) * 2013-04-10 2015-07-29 饶攀 一种功能性食品组合物及其制备方法
FR3007418B1 (fr) * 2013-06-21 2015-07-17 Interoleagineuse D Assistance Et De Dev S I A Soc Composition lipidique a base de triacylglycerol
CN104247786A (zh) * 2013-06-26 2014-12-31 孙志刚 一种正营养动植物油混合健康双合食用油
CN104247787A (zh) * 2013-06-26 2014-12-31 孙志刚 一种正营养动植物油混合普健康经济型a级双合食用油
CN104413167A (zh) * 2013-08-20 2015-03-18 孙志刚 一种日摄入量35克以上人群24种正营养食用油各种健康指标的脂肪酸科学配比
CN104413168A (zh) * 2013-08-20 2015-03-18 孙志刚 一种日摄入量30-35克人群24种正营养食用油各种健康指标的脂肪酸科学配比
CN104413170A (zh) * 2013-08-20 2015-03-18 孙志刚 一种日摄入量25-30克人群24种正营养食用油各种健康指标的脂肪酸科学配比
CN105658084A (zh) * 2013-10-23 2016-06-08 英派尔科技开发有限公司 食品添加剂、食品包装添加剂及其用途
EP3101138B1 (en) * 2013-12-04 2021-05-05 Nippon Suisan Kaisha, Ltd. Microbial oil, method for manufacturing microbial oil, concentrated microbial oil, and method for manufacturing concentrated microbial oil
CN103622023B (zh) * 2013-12-13 2015-12-09 许伯宗 一种前列腺保健品及其制备方法
CN103610835B (zh) * 2013-12-17 2015-07-15 刘凤阁 一种治疗眼底出血的药剂
WO2015112581A1 (en) 2014-01-21 2015-07-30 The Medical College Of Wisconsin, Inc. Methods for selective inhibition of pluripotent stem cells
CN104173255A (zh) * 2014-08-11 2014-12-03 杨磊 舒缓止痒的平衡理肤水
WO2016078088A1 (zh) * 2014-11-21 2016-05-26 深圳华大基因科技有限公司 美藤果油在调节动物肠道菌群中的用途
CN104435907A (zh) * 2014-12-29 2015-03-25 河南天纳图生物科技有限公司 一种用于畜禽催肥的复方发酵型中药及其制备方法
CN104740444A (zh) * 2015-04-07 2015-07-01 范永启 具有提神功效的复方精油喷雾剂
CN107529807A (zh) 2015-05-04 2018-01-02 酶学技术有限公司 用于改善睡眠的脂质组合物
KR101744203B1 (ko) * 2016-01-12 2017-06-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
MA43682A (fr) * 2016-02-26 2018-11-28 Nogra Pharma Ltd Procédés de traitement de l'intolérance au lactose
WO2017155898A1 (en) * 2016-03-07 2017-09-14 Nature's Sunshine Products, Inc. Methods and compositions to improve weight loss and cardiometabolic health beyond diet and exercise
JP7022955B2 (ja) 2016-03-17 2022-02-21 国立研究開発法人農業・食品産業技術総合研究機構 飲食物及びスクリーニング方法
EP3532030A4 (en) 2016-10-31 2020-04-22 The Cleveland Clinic Foundation CAPRIC ACID AND MYRISTIC ACID COMPOSITIONS FOR TREATING CONDITIONS
JP7013645B2 (ja) * 2016-11-14 2022-02-15 日油株式会社 リパーゼ活性阻害剤
CN106942678A (zh) * 2017-03-06 2017-07-14 楚雄泰恒工贸有限责任公司 松露芝士核桃仁及其制备方法
CA3063110A1 (en) 2017-05-12 2018-11-15 Housey Pharmaceutical Research Laboratories, L.L.C. Plant extracts with anti-diabetic and other useful activities
CN107439888A (zh) * 2017-08-31 2017-12-08 广州赛莱拉干细胞科技股份有限公司 一种糖尿病人服用的组合物及其制备方法
CN107629863A (zh) * 2017-09-30 2018-01-26 三江县善茶轩工艺品有限公司 富硒茶籽油的制备方法
CN107858202B (zh) * 2017-11-17 2021-06-08 湖南日恋茶油股份有限公司 富硒茶油及其加工工艺
KR20210125047A (ko) 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
WO2020165743A1 (en) * 2019-02-11 2020-08-20 Bhookhahaathi Hospitality Private Limited A nutraceutical composition for preventing bad breath and boosting immunity
EP4132483A1 (en) * 2020-04-10 2023-02-15 The Procter & Gamble Company Compositions and methods for treating hot flashes
CN112956543A (zh) * 2021-04-05 2021-06-15 江南大学 一种油脂组合物的调配方法

Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784849A (en) * 1983-08-15 1988-11-15 Tutsky Ronald J Skin care and shaving compositions
US5464643A (en) * 1989-09-22 1995-11-07 The Procter & Gamble Company Low fat fried snack
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5962062A (en) * 1996-06-27 1999-10-05 Nestec S.A. Dietetically balanced milk product
US6036984A (en) * 1995-06-01 2000-03-14 Nestec Ltd. Complete, nutritionally balanced coffee drink
US6156369A (en) * 1999-01-04 2000-12-05 Eger; Shaul Food spreads
US6159507A (en) * 1995-07-04 2000-12-12 Suntory Limited Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier
US20020025983A1 (en) * 2000-07-04 2002-02-28 Horrobin David Frederick Vitamin K and essential fatty acids
US20020137749A1 (en) * 1999-09-30 2002-09-26 Drugtech Corporation Formulation for menopausal women
US20030072787A1 (en) * 2000-06-01 2003-04-17 Wilson Mark E. Animal food and method
US20030091651A1 (en) * 2001-06-28 2003-05-15 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
US6630192B2 (en) * 1995-04-07 2003-10-07 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US20030207971A1 (en) * 2001-11-27 2003-11-06 React Of Delafield Llc Emollient gel
US20030225731A1 (en) * 2002-06-03 2003-12-04 Edward Vidgen System and method for optimized dietary menu planning
US20040001874A1 (en) * 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
US20040024065A1 (en) * 2002-03-11 2004-02-05 Watkins Steven M. Novel metabolic targets and markers
US20040048919A1 (en) * 2002-07-02 2004-03-11 Dreon Darlene M. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20040063205A1 (en) * 2002-09-27 2004-04-01 Rongxiang Xu Composition and method for culturing potentially regenerative cells and functional tissue-organs in vitro
US20050019423A1 (en) * 2004-09-21 2005-01-27 Bodybio Corporation Method for treating amyotrophic lateral sclerosis
US20050042256A1 (en) * 2001-08-08 2005-02-24 Jacques Decombaz Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level
EP1510133A1 (en) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
US20050054621A1 (en) * 2002-01-31 2005-03-10 Einav Gako-Golan Fractionation of phytosterol esters in oil
US20050054724A1 (en) * 2003-09-05 2005-03-10 Mustad Vikkie A. Lipid system and methods of use
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US20050245610A1 (en) * 2004-04-16 2005-11-03 Solvay Pharmaceuticals Gmbh Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
US20060068076A1 (en) * 2002-09-04 2006-03-30 Nestec S.A. Process for preparing an oil containing one or more long-chain polyunsaturated fatty acids derived from biomass; foodstuff or nutritional, cosmetic or pharmaceutical composition containing it
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US20060127504A1 (en) * 2004-12-13 2006-06-15 Brian Peskin Medicament for treatment of cancer and other diseases
US20060233863A1 (en) * 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
US20060241080A1 (en) * 2003-10-22 2006-10-26 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060276373A1 (en) * 2004-01-23 2006-12-07 Bazan Nicolas G Neuroprotective complex for treatment of cerebral ischemia and injury
US20060280840A1 (en) * 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070010480A1 (en) * 2003-05-28 2007-01-11 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Dietary food items for a weight control or weight loss diet
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
US20070082063A1 (en) * 2005-10-11 2007-04-12 Douglas Bibus Risk assessment and correction of membrane damage of the upper GI tract
US20070122452A1 (en) * 2003-12-22 2007-05-31 Wakunaga Pharmaceuticla Co., Ltd Fat composition
US20070154498A1 (en) * 2005-12-09 2007-07-05 Bortz Jonathan D Intravenous essential fatty acid emulsion
US20080019860A1 (en) * 2006-07-21 2008-01-24 Novus International Inc. Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
US20080058415A1 (en) * 2003-10-22 2008-03-06 Avidor Shulman Lipid Preparation for Enhancing Mineral Absorption
US20080069932A1 (en) * 2004-04-28 2008-03-20 Kao Corporation Oil or Fat Composition
US20080085322A1 (en) * 2001-06-28 2008-04-10 Rongxiang Xu Methods and compositions for activating regenerative stem cells from bone marrow
US20080090908A1 (en) * 2003-05-14 2008-04-17 Btg International Limited Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease
US20080145506A1 (en) * 2006-12-18 2008-06-19 Bodybio, Inc. Food compositions and products containing balanced ratio of essential fatty acids
US7416752B2 (en) * 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
US20080254017A1 (en) * 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
US20080260859A1 (en) * 2004-10-13 2008-10-23 Gudrun Claus-Herz Composition Containing Omega-3 Fatty Acids and Omega-6 Fatty Acids
US20080269330A1 (en) * 2004-11-11 2008-10-30 N.V. Nutricia Nutrition Containing Fat Blend
US20080268130A1 (en) * 2007-04-11 2008-10-30 Conopco, Inc. D/B/A Unilever Edible fat continuous spreads
US20090005447A1 (en) * 2001-03-27 2009-01-01 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
US20090011075A1 (en) * 2005-04-28 2009-01-08 Avidor Shulman Polar Lipid Mixtures, their Preparation and Uses
US20090018193A1 (en) * 1999-02-17 2009-01-15 Pfizer Italia S.R.L. Essential fatty acids in the prevention of cardiovascular events
US20090220649A1 (en) * 2005-03-14 2009-09-03 Sapporo Holding Limited Nutritionally Balanced Food or Beverage Product
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0353869A (ja) * 1989-07-21 1991-03-07 Nippon Oil & Fats Co Ltd 高度不飽和脂肪酸を含む食品
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
US5780451A (en) 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
CA2147109A1 (en) * 1994-04-18 1995-10-19 Gregory A. Reinhart Pet food product containing omega-6 and omega-3 fatty acids and process for reducing inflammatory skin responses
DE19528461A1 (de) * 1995-08-03 1997-02-06 Braun Melsungen Ag Präparat zur Ernährung
DE19948652A1 (de) 1999-10-01 2001-04-05 Yasmin Keschmiri Zusammensetzung aus Nahrungsmitteln, ihre Herstellung und ihre Verwendung als Aphrodisiakum und Vitaltonikum
ATE268998T1 (de) * 1999-11-24 2004-07-15 Iams Company Verfahren zur erhöhung der reproduzierenden leistung von hunden und katzen
RU2158514C1 (ru) 2000-04-03 2000-11-10 Болобан Леонид Григорьевич Масло льняное пищевое
US6592863B2 (en) 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
JP4116844B2 (ja) * 2001-09-13 2008-07-09 花王株式会社 油脂組成物
US7214491B2 (en) * 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
DE10347970A1 (de) * 2003-10-09 2005-05-04 Broekelmann & Co Oelmuehle Gmb Speiseölmischung
CN1997425B (zh) * 2004-07-01 2010-10-13 雀巢技术公司 犬骨关节炎饮食配方
DE102004034640A1 (de) * 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
ES2254018B2 (es) * 2004-11-16 2009-01-01 Universidad Autonoma De Madrid Mezcla oleosa de ingredientes bioactivos naturales para la preparacion de un producto alimenticio enriquecido.
RU2305416C2 (ru) 2005-05-23 2007-09-10 Тихоокеанский Государственный Экономический Университет (Тгэу) Пищевая эмульсионная паста и способ ее получения
JP4432882B2 (ja) 2005-11-17 2010-03-17 Ｔｄｋ株式会社 積層型電子部品およびその製造方法
AU2007204347B2 (en) 2006-01-09 2012-05-17 Nestec S.A. Treatment of stressed patients
CN101505609B (zh) * 2006-08-11 2013-07-17 花王株式会社 油脂组合物
US20090264520A1 (en) 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof

Patent Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784849A (en) * 1983-08-15 1988-11-15 Tutsky Ronald J Skin care and shaving compositions
US5464643A (en) * 1989-09-22 1995-11-07 The Procter & Gamble Company Low fat fried snack
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
US6630192B2 (en) * 1995-04-07 2003-10-07 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
US5843497A (en) * 1995-04-07 1998-12-01 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US7229653B2 (en) * 1995-04-07 2007-06-12 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serium by balancing saturated and polyunsaturated dietary fatty acids
US20030198728A1 (en) * 1995-04-07 2003-10-23 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serium by balancing saturated and polyunsaturated dietary fatty acids
US6036984A (en) * 1995-06-01 2000-03-14 Nestec Ltd. Complete, nutritionally balanced coffee drink
US6159507A (en) * 1995-07-04 2000-12-12 Suntory Limited Food composition containing an omega-6/omega-3 unsaturated fatty acid balance modifier
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5962062A (en) * 1996-06-27 1999-10-05 Nestec S.A. Dietetically balanced milk product
US6156369A (en) * 1999-01-04 2000-12-05 Eger; Shaul Food spreads
US20090018193A1 (en) * 1999-02-17 2009-01-15 Pfizer Italia S.R.L. Essential fatty acids in the prevention of cardiovascular events
US20050106266A1 (en) * 1999-09-30 2005-05-19 Levinson R. S. Formulation for menopausal women
US20020173510A1 (en) * 1999-09-30 2002-11-21 Drugtech Corporation Formulation for menopausal women
US20020137749A1 (en) * 1999-09-30 2002-09-26 Drugtech Corporation Formulation for menopausal women
US20090068289A1 (en) * 1999-09-30 2009-03-12 Drugtech Corporation Formulation for menopausal women
US20030072787A1 (en) * 2000-06-01 2003-04-17 Wilson Mark E. Animal food and method
US20020025983A1 (en) * 2000-07-04 2002-02-28 Horrobin David Frederick Vitamin K and essential fatty acids
US20090005447A1 (en) * 2001-03-27 2009-01-01 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
US20040115243A1 (en) * 2001-06-28 2004-06-17 Rongxiang Xu Compositions for oral delivery of nutrients and pharmaceuticals
US20080131528A1 (en) * 2001-06-28 2008-06-05 Rongxiang Xu Methods and compositions for treating or preventing neurodegenerative diseases
US20080096854A1 (en) * 2001-06-28 2008-04-24 Rongxiang Xu Composition and method for treating or preventing gastrointestinal cancer
US20080089945A1 (en) * 2001-06-28 2008-04-17 Rongxiang Xu Methods and compositions for promoting normal cell growth and inhibiting cancer cell growth
US20080085322A1 (en) * 2001-06-28 2008-04-10 Rongxiang Xu Methods and compositions for activating regenerative stem cells from bone marrow
US20030091651A1 (en) * 2001-06-28 2003-05-15 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
US20070166374A1 (en) * 2001-06-28 2007-07-19 Rongxiang Xu Composition and method for tissue repair and regeneration
US20060198898A1 (en) * 2001-06-28 2006-09-07 Rongxiang Xu Method for Preventing Ulceration or Irritation of Mucosa
US20050042256A1 (en) * 2001-08-08 2005-02-24 Jacques Decombaz Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level
US20030207971A1 (en) * 2001-11-27 2003-11-06 React Of Delafield Llc Emollient gel
US20050054621A1 (en) * 2002-01-31 2005-03-10 Einav Gako-Golan Fractionation of phytosterol esters in oil
US20040024065A1 (en) * 2002-03-11 2004-02-05 Watkins Steven M. Novel metabolic targets and markers
US20060141550A1 (en) * 2002-03-11 2006-06-29 Watkins Steven M Novel metabolic targets and markers
US20030225731A1 (en) * 2002-06-03 2003-12-04 Edward Vidgen System and method for optimized dietary menu planning
US20040001874A1 (en) * 2002-06-24 2004-01-01 Vital Living, Inc. Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
US20040048919A1 (en) * 2002-07-02 2004-03-11 Dreon Darlene M. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060068076A1 (en) * 2002-09-04 2006-03-30 Nestec S.A. Process for preparing an oil containing one or more long-chain polyunsaturated fatty acids derived from biomass; foodstuff or nutritional, cosmetic or pharmaceutical composition containing it
US20040063205A1 (en) * 2002-09-27 2004-04-01 Rongxiang Xu Composition and method for culturing potentially regenerative cells and functional tissue-organs in vitro
US20060292692A1 (en) * 2002-09-27 2006-12-28 Rongxiang Xu Potentially regenerative cells and functional tissue-organs in vitro
US20060233863A1 (en) * 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
US20080090908A1 (en) * 2003-05-14 2008-04-17 Btg International Limited Use of Triglyceride Oils Containing Gamma-Linolenic Acid Residues and Linoleic Acid Residues for the Treatment of Neurodegenerative Disease
US20070010480A1 (en) * 2003-05-28 2007-01-11 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Dietary food items for a weight control or weight loss diet
EP1510133A1 (en) * 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
US20080039525A1 (en) * 2003-09-05 2008-02-14 Mustad Vikkie A Lipid System and Methods of Use
US7759507B2 (en) * 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
US20050054724A1 (en) * 2003-09-05 2005-03-10 Mustad Vikkie A. Lipid system and methods of use
US20050130937A1 (en) * 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US20060241080A1 (en) * 2003-10-22 2006-10-26 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20080058415A1 (en) * 2003-10-22 2008-03-06 Avidor Shulman Lipid Preparation for Enhancing Mineral Absorption
US20050100621A1 (en) * 2003-11-07 2005-05-12 Popp Karl F. Dermatological compositions
US20070122452A1 (en) * 2003-12-22 2007-05-31 Wakunaga Pharmaceuticla Co., Ltd Fat composition
US7416752B2 (en) * 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
US20060276373A1 (en) * 2004-01-23 2006-12-07 Bazan Nicolas G Neuroprotective complex for treatment of cerebral ischemia and injury
US20050245610A1 (en) * 2004-04-16 2005-11-03 Solvay Pharmaceuticals Gmbh Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
US20080069932A1 (en) * 2004-04-28 2008-03-20 Kao Corporation Oil or Fat Composition
US20050019423A1 (en) * 2004-09-21 2005-01-27 Bodybio Corporation Method for treating amyotrophic lateral sclerosis
US20080260859A1 (en) * 2004-10-13 2008-10-23 Gudrun Claus-Herz Composition Containing Omega-3 Fatty Acids and Omega-6 Fatty Acids
US20060088574A1 (en) * 2004-10-25 2006-04-27 Manning Paul B Nutritional supplements
US20080269330A1 (en) * 2004-11-11 2008-10-30 N.V. Nutricia Nutrition Containing Fat Blend
US20060127504A1 (en) * 2004-12-13 2006-06-15 Brian Peskin Medicament for treatment of cancer and other diseases
US20090220649A1 (en) * 2005-03-14 2009-09-03 Sapporo Holding Limited Nutritionally Balanced Food or Beverage Product
US20090011075A1 (en) * 2005-04-28 2009-01-08 Avidor Shulman Polar Lipid Mixtures, their Preparation and Uses
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20060280840A1 (en) * 2005-05-24 2006-12-14 Robertson Marion G Universal protein formulation meeting multiple dietary needs for optimal health and enhancing the human immune system
US20070004639A1 (en) * 2005-07-01 2007-01-04 Bodybio, Inc. Methods and compositions for treating Parkinson's disease
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
US20070082063A1 (en) * 2005-10-11 2007-04-12 Douglas Bibus Risk assessment and correction of membrane damage of the upper GI tract
US20070154498A1 (en) * 2005-12-09 2007-07-05 Bortz Jonathan D Intravenous essential fatty acid emulsion
US20080254017A1 (en) * 2006-06-19 2008-10-16 Bodybio, Inc. Methods and compositions for treating symptomes of diseases related to imbalance of essential fatty acids
US20080019860A1 (en) * 2006-07-21 2008-01-24 Novus International Inc. Liquid monophasic lipid-soluble antioxidant compositions and processes for making the compositions
US20080145506A1 (en) * 2006-12-18 2008-06-19 Bodybio, Inc. Food compositions and products containing balanced ratio of essential fatty acids
US20080268130A1 (en) * 2007-04-11 2008-10-30 Conopco, Inc. D/B/A Unilever Edible fat continuous spreads
US20100267826A1 (en) * 2009-04-20 2010-10-21 The Board Of Trustees Of The Leland Stanford Junior University Treatment of ischemic episodes and cerebroprotection through Prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
"A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer" by Williams et al., Nutrition Res. 31, 1-8 (2011). *
"Dietary n-6 and n-3 polyunsaturated fatty acids: From biochemistry to clinical implications in cardiovascular prevention" by Russo, Biochem. Pharmacol. 77, 937-46 (2009). *
"Dietary Omega-3 Fatty Acid, Ratio of Omega-6 to Omega-3 Intake, Inflammation, and Survival in Long-term Hemodialysis Patients" by Noori et al., Am. J. Kidney Dis. 58, 248-56 (2011). *
"Dietary ratio of n-6 to n-3 polyunsaturated fatty acids and periodontal disease in community-based older Japanese: A 3-year follow-up study" by Iwasaki et al., Prostagland. Leukot. Essent. Fatty Acids 85, 107-12 (2011). *
"dosage" in www.thefreedictionary.com/dosage (retrieved from the internet on 4/1/2014) *
"Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation" by Wan et al., Arterioscler. Thromb. Vasc. Biol. 30, 2487-94 (2010). *
"Essential Fatty Acids, DHA and Human Brain" by Singh, Indian J. Pediat. 72, 239-42 (2005). *
"Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases" by Simopoulos, Biomed. Pharmacother. 60, 502-27 (2006). *
"Olive Trees and Honey" by Marks, Wiley Publishing (Hoboken, NJ), p. 20 (2005). *
"Olives Nutrient Analysis" in http://web.archive.org/web/20060314112106/http://www.whfoods.com/genpage.php?tname=nutrientprofile&dbid=111 (published: March 14, 2006) (retrieved from the internet March 4, 2015) *
"Olives" in web.archive.org/web/ 20061231074543/ http://www.whfoods.com/genpage.php?tname=nutrient profile&dbid=111 (published: December 31, 2006) (retrieved from the internet 4/1/2014) *
"Olives" in web.archive.org/web/20060314112112/http:// www.whfoods.com/genpage.php?pfriendly=1&tname=foodspice&dbid=46 (published: March 14, 2006) (retrieved from the internet March 4, 2015) *
"Omega 3 - Omega 6: What is right for the liver?" by El-Badry et al., J. Hepatol. 47, 718-25 (2007). *
"Omega-3, 6 and 9 Fatty Acids" in www.uccs.edu/Documents/peakfood/hlthTopics/Omega-3_6_and_9_ Fats.pdf (retrieved from the internet 4/1/2014) *
"Omega-6 Fatty Acids and Coronary Artery Disease: The Pros and Cons" by Dubnov et al., Curr. Athero. Reports 6, 441-46 (2004). *
"Scientific Psychic" in web.archive.org/web/20061230085216/http:// www.scientificpsychic.com/fitness/fattyacids1.html (retrieved from the internet 4/1/2014) *
"Soybeans Health Benefits" in web. archive.org/web/20061231075909/http://www.whfoods.com /genpage.php?pfriendly=1&tname=foodspice&dbid=79 (published: December 31) (retrieved from the internet on 4/1/2014) *
"Soybeans Nutritional Analysis" in web.archive. org/web/20061109224501/http://www.whfoods. com/genpage.php?pfriendly=1&tname=nutrient profile&dbid=17 (retrieved from the internet on 4/1/2014) *
"Sunflower Seeds Health Benefits" in web.archive.org/web/20061231 072831 / http://www. whfoods.com/genpage.php?tname=foodspice&dbid=57 (published: December 31, 2006) (retrieved from the internet on 4/1/2014) *
"Sunflower Seeds Nutritional Analysis" in web.archive.org/web/2006 1109215807/http://www .whfoods.com/genpage.php?tname=nutrientprofile&dbid=127 (retrieved from the internet on 4/1/2014) *
"The Olive - Polyphenols and Antioxidant Activity" in www.olivepowder.com/polyphenols.html, "Omega-3, 6 and 9 Fatty Acids" in www.uccs.edu/Documents/peakfood/hlthTopics/Omega-3_6_and_9_ Fats.pdf (retrieved from the internet 4/1/2014) *
"The Omega-3, 6 and 9 of Cooking Oils" by Anonymous (retrieved on July 12, 2011 from http://theconsciouslife.com). *
"The Omega-6/Omega-3 Ratio and Cardiovascular Disease Risk: Uses and Abuses" by Harris, Curr. Athero. Rep. 8, 453-59 (2006). *
"The omega-6/omega-3 ratio is of importance" by Strandvik, Prostagland. Leukot. Essent. Fatty Acids 85, 405-06 (2011). *
"Walnuts Health Benefits" in web.archive.org/web/20061212181741/http://www.whfoods.com/ genpage.php?tname=foodspice&dbid=99 (published: December 12, 2006) (retrieved from the internet on 4/1/2014) *
"Walnuts Nutrient Analysis" in http://web.archive.org/web/20061109221127/ http://www. whfoods.com/genpage.php?tname=nutrientprofile&dbid=132 (published: November 9, 2006) (retrieved from the internet March 4, 2015) . *
"Walnuts Nutritional Analysis" in web.archive.org/web/ 20061109224756/http://www.whfoods.com/genpage. php?pfriendly=1&tname=nutrientprofile&dbid=132 (retrieved from the internet on 4/1/2014) *
"Walnuts" in http://www.whfoods.com/genpage.php?tname= foodspice&dbid=99 (published: November 9, 2006) (retrieved from the internet March 4, 2015) *
101 Guidelines in www.uspto.gov/patents/law/exam/examguide.jsp (retrieved from the internet 4/1/2014) *
101 Guidelines Slides in www.uspto.gov/ patents/law/exam/myriad-mayo_slides_20140319.pdf (retrieved from the internet on 4/1/2014) *
BHT in http://bakerpedia.com/bht (retrieved from the inernet August 10, 2014) *
Black Olives Iron Gluconate in www.sfi-egypt.com/faqs. asp (retrieved from the internet August 10, 2014) *
Black Pearls Olives" in http://www.labelwatch.com.product pop.php?id=13133 (2007) (retrieved from the internet August 10, 2014) *
Calories in www.caloriesperhour.com /tutorial_gram.php) (retrieved from the internet on 4/1/2014) *
Corn Oil Nutritional Analysis" in http://www.fda.gov/ ohrms/dockets/dockets/06p0243/06p-0243-cp00001-059-APPENDIX-S1-NUTRIENT%20ANALYSISCORNOIL.pdf (retrieved from the inernet August 10, 2014) *
Diamond Walnuts in http://www.labelwatch.com/product_pop.php?id=1577 (published:2007) (retrieved from the inernet August 10, 2014) *
Enteral Administration at en.wikipedia.org/wiki/Enteral_administration (retrieved from the Internet 4/4/2014) *
Formulation in http://en.wikipedia.org/wiki/Formulation (retrieved from the internet on 4/1/2014) *
Master, M. in Men's Health (www.menshealth.com/mhlists/facts_about_nutritional_ fiber/printer.php), "The Truth About Fiber" (retrieved from the internet August 10, 2014) *
Olive Oil Nutrition Facts at http://nutritiondata. self.com/facts/fats-and-oils/509/2) (retrieved from the internet March 4, 2015) *
Vinson et al. in Food & Nutrition 3(2), 93 - 98 (2012). *
Walnut Oil Health Benefits (www.seedsofsustainability.org/uncategorized/health-benefits-of-walnut-oil/) (retrieved from the internet March 4, 2015) *
Walnut Oil Nutrition Facts (http://nutritiondata.self.com/facts/fats -and-oils/589/2) (retrieved from the internet March 4, 2015) *
Walnuts Nutritional Analysis" in web.archive.org/web/ 20061231074543/http://www.whfoods.com/genpage.php?tname=nutrient profile&dbid=132 (retrieved from the internet August 10, 2014) *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011080580A3 (es) * 2009-12-30 2011-08-25 Team Foods Colombia S.A. Esparcible con bajo contenido de grasa total hecho con aceites vegetales y fitoesteroles
WO2011113128A1 (pt) * 2010-03-18 2011-09-22 Leitao De Vasconcelos Paulo Roberto Preparados a base de óleos de vegetais e peixes usados como suplemento nutricional
EP2584920B1 (en) 2010-06-28 2017-12-13 Nestec S.A. Hypocaloric, high protein nutritional compositions and methods of using same
WO2012135498A3 (en) * 2011-03-29 2013-04-04 Dr. Baker Says, Inc. Nutritional supplement comprising nut and seed oil composition
US10863761B2 (en) 2011-07-12 2020-12-15 Impossible Foods Inc. Methods and compositions for consumables
US9011949B2 (en) 2011-07-12 2015-04-21 Impossible Foods Inc. Methods and compositions for consumables
US10327464B2 (en) 2011-07-12 2019-06-25 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9943096B2 (en) 2011-07-12 2018-04-17 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9700067B2 (en) 2011-07-12 2017-07-11 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9808029B2 (en) 2011-07-12 2017-11-07 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US10039306B2 (en) 2012-03-16 2018-08-07 Impossible Foods Inc. Methods and compositions for consumables
US20140065279A1 (en) * 2012-09-06 2014-03-06 Michael Roizen Edible oils for frying and cooking foods having health benefits
EP2716167A1 (en) * 2012-10-02 2014-04-09 Lunamed AG Non-pharmaceutical composition comprising short chain fatty acids
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US10986848B2 (en) 2013-01-11 2021-04-27 Impossible Foods Inc. Methods and compositions for consumables
US9826772B2 (en) 2013-01-11 2017-11-28 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US11224241B2 (en) 2013-01-11 2022-01-18 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US11219232B2 (en) 2013-01-11 2022-01-11 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US11013250B2 (en) 2013-01-11 2021-05-25 Impossible Foods Inc. Methods and compositions for consumables
US10993462B2 (en) 2013-01-11 2021-05-04 Impossible Foods Inc. Methods and compositions for consumables
US10172381B2 (en) 2013-01-11 2019-01-08 Impossible Foods Inc. Methods and compositions for consumables
US10314325B2 (en) 2013-01-11 2019-06-11 Impossible Foods Inc. Methods and compositions for affecting the flavor and aroma profile of consumables
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ES2528331A1 (es) * 2013-08-06 2015-02-06 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta Del Hierro Composición con efecto en la salud ósea y cardiovascular
CN103404613A (zh) * 2013-08-22 2013-11-27 宁夏吴忠市国海粮油有限公司 一种葵花调和油及其加工工艺
US10798958B2 (en) 2014-03-31 2020-10-13 Impossible Foods Inc. Ground meat replicas
US10172380B2 (en) 2014-03-31 2019-01-08 Impossible Foods Inc. Ground meat replicas
US11439166B2 (en) 2014-03-31 2022-09-13 Impossible Foods Inc. Ground meat replicas
US11819041B2 (en) 2014-03-31 2023-11-21 Impossible Foods Inc. Ground meat replicas
EP3247224A4 (en) * 2014-09-01 2018-08-15 Vadakkemuri, Mathew Jolly Optimized nutrient food
US20170360073A1 (en) * 2014-11-07 2017-12-21 Jolly Mathew Vadakkemuri Optimized nutrient fatty acid composition
US20160219921A1 (en) * 2015-02-04 2016-08-04 Natalja Klein Super food beverage
CN106819153A (zh) * 2015-12-04 2017-06-13 金士力佳友(天津)有限公司 一种含美藤果油和深海鱼油的调和油及其应用
EP3420822A1 (en) * 2017-06-23 2019-01-02 OliVita AS Combination of oils
EP3876741A4 (en) * 2018-11-09 2022-08-31 L-Nutra NUTRIENT BAR FOR INTERMITTENT FASTING SIMULATE
US11854684B2 (en) 2020-12-29 2023-12-26 Kpn Innovations, Llc. Methods and systems for nourishment refinement using psychiatric markers
CN116421666A (zh) * 2023-04-07 2023-07-14 云南德彩堂生物医药科技有限公司 一种稳定高效抗骨质疏松的油脂组合物，其制备方法及应用

Also Published As

Publication number Publication date
WO2009131939A9 (en) 2010-05-06
KR102030851B1 (ko) 2019-10-10
MX2010011544A (es) 2010-12-20
JP6879597B2 (ja) 2021-06-02
MX2019010738A (es) 2019-11-05
WO2009131939A3 (en) 2010-03-11
AU2009239499C1 (en) 2013-11-07
JP2020127400A (ja) 2020-08-27
EA201071206A1 (ru) 2011-08-30
JP2014176385A (ja) 2014-09-25
CA2759551C (en) 2021-03-16
ZA201008232B (en) 2012-02-29
EP2278885A4 (en) 2013-08-28
KR20110004447A (ko) 2011-01-13
MY157040A (en) 2016-04-15
IL208858A0 (en) 2011-01-31
EP3305083A1 (en) 2018-04-11
CO6321198A2 (es) 2011-09-20
AU2009239499B2 (en) 2013-03-21
JP2018064563A (ja) 2018-04-26
WO2009131939A2 (en) 2009-10-29
US10292958B2 (en) 2019-05-21
AU2009239499A1 (en) 2009-10-29
JP7007010B2 (ja) 2022-01-24
CA2759551A1 (en) 2009-10-29
KR102038118B1 (ko) 2019-10-29
IL208858A (en) 2017-12-31
KR20170129289A (ko) 2017-11-24
JP2011518223A (ja) 2011-06-23
BRPI0910852A2 (pt) 2018-05-29
EP2278885A2 (en) 2011-02-02
US20120100223A1 (en) 2012-04-26
CN102065699A (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
JP6879597B2 (ja) 脂質含有組成物およびその使用方法
JP2011518223A5 (ru)
CA2814053C (en) Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof
CN107105745A (zh) 优化的营养脂肪酸组合物
US20090203780A1 (en) Use of a Polyunsaturated Fatty Acid Compound
CN106535650A (zh) 磷虾油制剂和它们的用途
Shayo et al. Strategies to ameliorate endothelial dysfunction associated with metabolic syndrome, where are we?
ES2555032T3 (es) Compensación nutricional para dieta de tipo occidental
MANSOR et al. Effect of various dietary pattern on blood pressure management: A review
AU2015275258A1 (en) Optimized nutritional formulations, methods for selection of tailored diets therefrom, and methods of use thereof
Paolini et al. Nutrition in women between prevention and wellness

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASHA LIPID SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BHAGAT, URVASHI;REEL/FRAME:022563/0381

Effective date: 20090417

AS Assignment

Owner name: ASHA LIPID SCIENCES, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BHAGAT, URVASHI;REEL/FRAME:026219/0230

Effective date: 20110428

AS Assignment

Owner name: ASHA NUTRITION SCIENCES, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:ASHA LIPID SCIENCES, INC.;REEL/FRAME:028550/0308

Effective date: 20110425

STCV Information on status: appeal procedure

Free format text: APPLICATION INVOLVED IN COURT PROCEEDINGS

STCV Information on status: appeal procedure

Free format text: COURT PROCEEDINGS TERMINATED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION